End Stage Renal Disease
Conditions
Keywords
Kidney transplant, Cognitive function
Brief summary
The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.
Interventions
DRUGTacrolimus
The patient's physician will prescribe drug according to standard practice.
DRUGEverolimus
The patient's physician will prescribe drug according to standard practice.
Sponsors
Novartis Pharmaceuticals
University of Kansas Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* English speaking * able to sign informed consent * able to arrange transportation to and from study site * without acute stroke, concussion or traumatic brain injury * without acute medical issues at the time of participation * At least 12 weeks post Kidney transplant surgery
Exclusion criteria
* are claustrophobic or have other contra-indication for magnetic resonance imaging (MRI) * have hearing or visual impairment * are unable to read, write, speak or understand English * have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics * taking Envarsus at the time of recruitment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in cognitive function | Change from Baseline to Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| Change in cerebral blood flow | Change from Baseline to Week 12 |
Countries
United States
Outcome results
None listed